13D Filing: Baker Bros. Advisors and Mirati Therapeutics Inc. (MRTX)

Certain securities of the Issuer are held directly by Life Sciences,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the
sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling
members of Baker Brothers Life Sciences Capital (GP), LLC.

Certain securities of the Issuer are held directly by 14159,
a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole general partner
of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital (GP), LLC.

(e) Not applicable.

ITEM 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6 of this Schedule 13D is hereby supplemented and amended,
as the case may be, as follows:

The disclosure in Item 4 of the exercise of the 2017 Warrants
and the purchase of the Pre-Funded Warrants above is incorporated herein by reference. The form of warrant for the Pre-Funded Warrants
is incorporated by reference as Exhibit 99.1 and is incorporated by reference herein.

The disclosure in Item 4 of the Board Rights above is incorporated
herein by reference. The Board Observer and Director Rights Agreement is incorporated by reference as Exhibit 99.2 and is incorporated
by reference herein.

Item 7.

Material to be Filed as Exhibits

 

Exhibit	Description
99.1	Form of Warrant to Purchase Common Stock, dated November 16, 2017, by and between Mirati Therapeutics, Inc., 667, L.P., and Baker Brothers Life Sciences, L.P. (incorporated by reference to Exhibit 4.1 to the Issuer’s Form 8-K, filed with the SEC on November 16, 2017).

99.2	Board Observer and Director Rights Agreement, by and between Mirati Therapeutics, Inc., 667, L.P., Baker Brothers Life Sciences, L.P.  and 14159, L.P.